News and Announcements
Actinogen Medical CEO Interview
- Published September 23, 2016 11:18AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment. The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.
Please listen to Dr. Bill Ketelbey, Founder and CEO & Managing Director of Actinogen Medical below.
Executive Interviews
Navigating the Market Inflection Point: Exclusive Investor & Founder Meetups Across Australia
The market is at a genuine inflection point in mid-2025, with conflicting signals from AI breakthroughs and geopolitical shifts. This blog announces exclusive, intimate investor and founder meetups across Australia, designed to cut through the noise, reveal unfiltered truths about the H2 2025 outlook, and map the “smart money migration” to position participants for strategic advantage.
Bridging the Gap: Why Australian Capital is Crucial for India’s Trillion-Dollar Growth Story
Australia’s substantial savings pool is meeting India’s explosive growth. Learn how Creek Partners is building the crucial bridge for investors seeking to tap into India’s projected $7 trillion economy and its vibrant venture capital ecosystem.
Beyond the Hype: Strategic Digital Asset Investing for a New Financial Era
The financial world is undergoing a profound transformation driven by Digital Assets. Learn why hundreds of billions are pouring into new digital infrastructure, with stablecoins now outperforming Mastercard/Visa in transaction volume. This article guides investors beyond the hype to strategic digital asset investing, exploring yield, DePIN, DeFi, and AI+Blockchain for the new financial era. Discover more at Venture & Capital SYDNEY 2025.
Backed By Leading Investment Groups and Family Offices
